Heart failure with preserved ejection fraction (HFpEF) is a complex clinicalsyndrome with high morbidity and increasing socio-economic burden, compounded bythe lack of effective treatment options available to treat this disease.Sodium-glucose cotransporter-2 (SGLT2) inhibitors have previously been shown toimprove cardiovascular and renal outcomes in patients with type 2 diabetes andpatients with heart failure with reduced ejection fraction (HFrEF). This evidence concerns the gene SLC5A2 and heart failure.